LENEXA, Kan. & CYPRESS, Calif.--(BUSINESS WIRE)--Evogen is pleased to announce that it has entered into a non-exclusive License Agreement with Focus Diagnostics granting worldwide rights to incorporate Evogen proprietary and novel HyBeacons® PCR probe technology into their molecular diagnostic products and services. Focus Diagnostics, a leading molecular diagnostics company specializing in infectious disease testing, is a business of Quest Diagnostics, the world’s leading provider of diagnostic information services. Additional terms of the Agreement were not disclosed. HyBeacons probes are sequence specific hybridization probes containing two fluorophores per probe thereby creating a robust fluorescent signal. Since HyBeacons are not hydrolyzed during PCR amplification, positive confirmation of the amplicon is available by way of high definition melt curve analysis. HyBeacons are easy to design which offers the ability to multiplex different color probes for the identification of multiple targets in a single reaction. HyBeacons provide clear quantitative data during amplification and have proven capabilities with DNA and RNA targets.
